Received May 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AHACIMBM51LI | — |
The patient received the second dose of Shingrix on 22 May 2025; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 71-year-old female patient who received Herpes zoster (Shingrix) (batch number AHACIMBM51LI) for prophylaxis. Previously administered products included Shingrix (patient received the first dose of Shingrix on 20 January 2020). On 22-MAY-2025, the patient received the 2nd dose of Shingrix. On 22-MAY-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: The patient received the second dose of Shingrix on 22 May 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 26-MAY-2025 The reporter was the patient. Patient asked what information do we currently have regarding Shingrix effectiveness when the two doses are widely separated, in my instance by more than five years? The patient received the first dose of Shingrix on 20th January 2020. The patient received the second dose of Shingrix on 22th May 2025, which led to drug dose administration interval too long